
Dr Carl Regillo provided an overview of topline results – and a deep dive into subgroup analyses – of DAVIO 2 trial data

Dr Carl Regillo provided an overview of topline results – and a deep dive into subgroup analyses – of DAVIO 2 trial data

Sydney M Crago, editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial, presented at the 2024 Angiogenesis Symposium

At this year's ESCRS meeting, industry leaders shared advice for young ophthalmologists–and what they wish they'd known earlier in their careers

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

At this year's American Academy of Ophthalmology meeting, Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America, spoke with us about three exciting new launches

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

In a conversation with Ophthalmology Times, Mary Elizabeth Hartnett, MD, FACS, discussed her AAO presentation, focusing on the impact of blindness and vision loss on women in the United States

Esen K. Akpek, MD, discussed her presentation at this year's American Academy of Ophthalmology meeting, covering recent advancements in artificial corneas

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Dr Ali Erginay of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging"

Attendees share their favorite moments and memories from the 2023 ESCRS meeting

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery"

We asked attendees and presenters to share their highlights from this year's ESCRS meeting, which included favorites from the official programme and beyond

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).

In the years to come, Ciliatech will release more data around their novel Cilioscleral Interposition Device (CID)

The future of refractive surgery is bright, thanks to OCTs and advances in laser technology

At the meeting, ZEISS Meditec Ophthalmology showcased the VISUMAX 800 and a host of new launches

The medical director for Optegra has piloted corneal workflows and trifocal lenses presented at the meeting

The director of Frankfurt’s Bürgerhospital eye hospital shared 7 years’ data on the iStent inject®

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

New cataract and refractive options from STAAR Surgical could come as early as this year